Wall Street : OREX Gets Props From Wall Street. LINK
Another Weight Loss Drug Gets Props from Wall Street
By Meghan Foley | More Articles
September 08, 2012
California-based Orexigen Therapeutics’s (NASDAQ:OREX) new weight-loss drug Contrave entered its final stage of clinical trials ahead schedule and garnered the attention of Credit Suisse, who is attempting to pick a winner from among the three new weight-loss pills set to hit markets soon.